Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 28;24:266. doi: 10.1186/s12859-023-05393-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — Overall survival curves of KMT2A positive patients in TARGET AML 1031 and AML 0531. A Odds ratio of the top enriched Cmap names and mechanisms of action (MOAs) identified through EFS Coxph regression analysis. B Overall survival curves of KMT2A fusion positive patients in TARGET AML 1031 (N = 220). Patients are classified by the ssGSEA score derived from genes affected by the HDAC inhibitor Vorinostat. C Overall survival curves of KMT2A fusion positive patients in TARGET AML 0531 (N = 46) validation cohort. Patients are classified by the ssGSEA score derived from genes affected by the HDAC inhibitor Vorinostat. D Cell-line sensitivity ranking based on IC50 values of Vorinostat. E Overall survival curves of KMT2A positive patients in TARGET AML 1031. Patients are classified by the ssGSEA score derived from genes affected by the ATPase inhibitor Thapsigargin. F Overall survival curves of KMT2A positive patients in TARGET AML 0531 validation cohort. Patients are classified by the ssGSEA score derived from genes affected by the ATPase inhibitor Thapsigargin. G Cell-line sensitivity ranking based on IC50 values of Thapsigargin